Table 1 Patient characteristics and outcome parameters

Age (median, IQR)

67 (55-75)

Male/female

33/20

SAPS II (median, IQR)

72 (63-80)

ICU mortality (n, %)

20 (38)

Maximal change in thickness (mean %, 95 % CI)

32 (27-37)

Aminoglycoside (AG) use (n, %)

15 (28)

 Maximal change in thickness in AG subgroup (mean %, SD)

38 (18)

 Maximal change in thickness in non-AG subgroup (mean %, SD)

30 (18)

P

0.367

Corticosteroids (CS) use (n, %)

26 (49)

 Maximal change in thickness in CS subgroup (mean %, SD)

34 (17)

 Maximal change in thickness in non-CS subgroup (mean %, SD)

29 (19)

P

0.160

Continuous neuromuscular blocking agents administration (n, %)

14 (28)

Single dose or more of neuromuscular blocking agents administration (n, %)

35 (66)

Sepsis on admission (n, %)

25 (47)

 Maximal change in thickness in sepsis subgroup (%, SD)

35 (28-42)

Sepsis during ICU stay (n, %)

45 (85)